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Systemic lupus erythematosus (SLE) is an autoimmune disorder that involves multiple organ systems and
typicallypresents as a chronic inﬂammatorydisease. Antibodies todouble-stranded (ds)DNAarepresent in
approximately 70% of patients and form nucleic acid containing immune complexes which activate den-
dritic cells through engagement of toll-like receptors, leading to a pro-inﬂammatory, pro-immunogenic
milieu. In addition, anti-dsDNA antibodies deposit in kidneys to initiate glomerulonephritis. Antibodies to
C1q have also been implicated in lupus nephritis and are found in 30e50% of patients. C1q is a known
suppressor of immune activation and C1q deﬁciency is the strongest risk factor for SLE.
We previously identiﬁed a subset of anti-DNA antibodies that binds the N-methyl-D-aspartate receptor.
We now show that both mouse and human anti-DNA antibodies with this speciﬁcity bind C1q. These
antibodies bind to Clq in glomeruli and exhibit decreased glomerular deposition in the absence of C1q.
We propose that this subset of anti-DNA antibodies participates in lupus pathogenesis through direct
targeting of C1q on glomeruli and also through removal of soluble C1q thereby limiting the ability of C1q
to mediate immune homeostasis.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disorder
primarily affecting women during their reproductive years. It is
characterized by activation of autoreactive B cells with ensuing
elevation in serum autoantibody titers. Autoantibodies against nu-
clear antigens are found in 95% ormore of lupus patients; antibodies
to double-stranded (ds) DNA are present in approximately 70% of
patients [1]. High titers of anti-dsDNA antibodies correlate with
disease activity, aremost common inpatientswith renal disease and
can be isolated fromglomeruli of patientswith lupus nephritis [2,3].
Indeed, many anti-dsDNA antibodies cross-react with glomerular
antigens [4]. Clinical involvementof the kidneysoccurs in50e80%of
lupuspatients during the course of their disease and renal pathology
is found in as many as 90% of patients at autopsy [5].
More recently, it has been demonstrated that lupus patients
with anti-DNA or anti-RNP antibodies experience systemic
inﬂammation as well as discrete target organ injury, with increased: þ1 516 562 2921.
).
r Ltd. Open access under CC BY-NC-Nexpression of type I interferon (IFN) inducible genes in peripheral
blood mononuclear cells [6]. This appears to result from activation
of plasmacytoid dendritic cells (pDCs) and secretion of IFN, medi-
ated in part by nucleic acid-containing immune complexes (IC) that
are internalized by activating Fc receptors (FcRs) and subsequently
engage toll-like receptors (TLRs) that recognize nucleic acid ligands
or even solely by engaging activating FcRs [7,8].
C1q is a 460 KDa protein formed by 6 homotrimeric subunits
containing an N-terminal collagen-like sequence and a C-terminal
globular region. It functions in the innate immune response to clear
pathogens by activation of the classical complement cascade [9].
Moreover, it contributes to the clearance of IC and apoptotic cells
from the circulation, an activity which is important for mainte-
nance of immune tolerance to self antigens [10]. C1q has also been
found to inhibit monocyte to DC differentiation, DC activation and
interferon production by plasmacytoid DCs (pDCs) and therefore
may also play a central role in preventing aberrant innate and
adaptive immune responses [11e13]. Although C1q deﬁciency is a
rare phenomenon, it provides the strongest genetic risk for lupus
[14]. Several receptors binding C1q have been identiﬁed in various
cell types including C1qRp (CD93); cC1qR (calreticulin), LAIR-1, CR1
and CD35 which bind the collagen region of C1q; gC1qR (multi-
ligand binding receptor) which binds to the globular domain of
C1q; and C1qR02 [13,15]. Engagement of each of these receptors
appears to initiate distinct cellular functions; for example,D license.
Fig. 1. Cross reactivity of R4A. a. R4A and an isotype control antibody were assayed by ELISA for binding to EADYG peptide. b. R4A and an isotype control antibody were assayed by
ELISA for binding to C1q. c. R4A was assayed by ELISA for binding to C1q in the presence of varying concentrations of EADYG or DWEYS peptide. d. R4A was assayed by ELISA for
binding to DNA in the presence of varying concentrations of C1q. e. R4A was assayed by ELISA for binding to C1q (solid line) and to the collagen tail of C1q (dotted line). f. R4A was
incubated with isolated glomeruli fromwild type and C1q/mice and binding was detected with a labeled antibody to mouse IgG. DAPI was used to visualize DNA in the glomeruli.
Results are representative of three different experiments. g. IgG binding to wild type or C1q/ kidney was quantitated after intravenous injection of infra-red-labeled R4A or MPC-
11 isotype control. Data from three separate experiments are represented as percent IDV signal within each experiment. h. R4A-AF488 binding to glomeruli following intravenous
administration to wild type and C1q/ mice, was assessed by microscopy and compared to control immunoglobulin MPC11-AF488.
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C1qR02 triggers a superoxide burst in neutrophils. Most impor-
tantly for an understanding of SLE, absence of C1q has been shown
to lead to enhance IFNa production by both human and murine
pDCs [17,18].Antibody to C1q has also been implicated in lupus nephritis, and
is found in 30e50% of lupus patients [19]. Indeed, antibody to C1q
correlatesmore strongly with renal disease than antibody to dsDNA
and increased serum levels of anti-C1q antibodies correlate with
ﬂares [20]. Since C1q together with natural IgM autoantibodies
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nization of apoptotic material and through engaging the inhibitory
LAIR-1 receptor on monocytes and DCs, it has been postulated that
anti-C1q antibodies might decrease the availability of C1q for this
tolerogenic function [21]. Anti-C1q antibodies may also contribute
to lupus pathogenesis by binding to IC in target organs. In support
of this model are data that monoclonal anti-C1q antibodies
administered to mice exacerbate glomerular immunoglobulin
deposition by anti-glomerular basement membrane antibodies
[22], although they do not induce disease by themselves.
Our laboratory has previously generated a murine mono-
clonal antibody R4A which binds to dsDNA [23]. By screening a
peptide library, we showed that R4A binds a consensus penta-
peptide sequence D/EWD/EYS/G. Immunization of BALB/c mice
with a multimeric conﬁguration of the DWEYS peptide induces
the formation of antibodies that cross-react with dsDNA, deposit
in glomeruli and induce proteinuria [24]. The consensus
sequence is present in the extracellular region of the NR2A and
NR2B subunits of the N-methyl-D-aspartate receptor (NMDAR) in
both mice and humans. In mice, antibodies to dsDNA and
DWEYS bind neuronal NMDAR, induce apoptosis and cause some
neuropsychiatric manifestations of lupus if they gain access to
brain tissue [25]. Antibodies cross-reactive with both dsDNA and
DWEYS peptide are present in approximately 40% of lupus pa-
tients [25].
R4A was also found to bind the decapeptide WCEADYGRCP in
the screen of the peptide library. Because R4A bound the consensus
pentapeptide D/EWD/EYS/G, we presumed it bound the EADYG
sequence which shares 4 of 5 amino acids with the consensus
sequence [26]. A peptide blast query using the EADYG peptide
sequence through the National Center for Biotechnology informa-
tion (NLM-NIH) search engine, identiﬁed a homologous sequence
present in the globular domain (GSEADSV) of the C1q A chain (NP
001002259.1, NCBI, NLM, NIH). We now demonstrate for the ﬁrst
time that antibodies to dsDNA cross-react with C1q and play a
potential role in the pathogenesis of lupus through deposition in
glomeruli.2. Material and methods
2.1. Mice
Female C1q/ C57BL/6J mice were obtained from Dr. Keith
Elkon, University of Washington and female C57BL/6J from Jackson
Laboratories (Bar Harbor, ME, USA). Mice were 8e16 weeks of age.2.2. ELISAs
Costar half-volume 96-well plates (Corning, NY) were used for
C1q NR2 A and B, and peptide ELISAs and Immulon 2HB 96-well
plates (Milford, MA) were used for DNA ELISAs. C1q was pur-
chased from Comptech (Tyler, TX) and adsorbed to 96-well plate
(50 mg/ml). NR2A and NR2B were expressed in a cell line and
extracted from an electrophoresis gel of cell lysate. Peptides were
purchased from AnaSpec Inc, San Jose, CA. DNA, C1q, the collagen
tail of C1q obtained by digestion of intact C1q, peptides or NR2A
and NR2B were added to plates and incubated overnight at 4 C
then blocked with 2% BSA in PBS for 1 h at RT. R4A antibody, IgG2b
control immunoglobulin (MPC-11 hybridoma, ATCC, Manassas,
VA), was added for 1 h at RT at various concentrations. C1q
collagen-tail of C1q was prepared as described in Ref. [27]. Re-
agents used in vivo experiments were tested for LPS content by
LAL (limulus amebocyte lysate) assay and were found to have less
than 0.05 EU/ml.2.3. Glomerular binding assay
Glomeruli were isolated from C1q/ or wild type C57BL/6J mice
[28,29]. Ten to 20 glomeruli were attached per slide and acetone
ﬁxed. Some slides were treated with DNAse (Sigma) at 100 mg/ml in
5 mM CaCl and 0.9% NaCl for 45 min at 37 C or with PBS alone.
After blocking with 10% goat serum, R4A mouse monoclonal anti-
DNA antibody mouse IgG2b control antibody (MCP-11) G11 hu-
man antibody to DNA anti-peptide antibody human IgG control
immunoglobulin (B1) or anti-C1q antibody (JL1, Pierce biotech-
nology, Rockford, IL) was added for 1 h at RT at 20 mg/ml. Secondary
antibodies were added at a 1:200 dilution for FITC-labeled anti-
mouse IgG (BD) or a 1:500 dilution for FITC-labeled anti-human IgG
(Inova diagnostics). DAPI was used at a 1:200 dilution from a stock
solution of 200 mg/ml. Puriﬁed C1q at 250 mg/ml was incubated
with G11 or anti-C1q for 30 min at RT prior to being added to
glomeruli.
2.4. Isolation of human anti-DWEYS antibodies
Lupus sera known to have antibodies reactive to DWEYS peptide
were incubated with a sepharose 4B resin coupled to DWEYS
peptide (AnaSpec Inc.) for 12 h at 4 C. The resin was washed
with PBS prior to elution of bound antibodies with a 0.2 M glycine
buffer pH 3.
2.5. Generation of human monoclonal antibody
The monoclonal G11 and B1antibodies were obtained from
blood B cells of a lupus patient as described [27].
2.6. In vivo administration of R4A
R4A and MPC-11 (IgG2b control) were labeled with Alexa Fluor
488 (AF488) according to manufacturer (Invitrogen, Grand Island,
NY). Two hundred micrograms of labeled R4A or MPC-11 were
injected intravenously in C57BL6/J mice. Kidneys were harvested
8 h later and frozen. Kidneys were processed in a cryostat and 10
micron sections were mounted on slides for microscopy.
Moreover, R4A or MPC-11 antibodies were labeled with infra-
red Dye (Licor, Lincoln, NE) and 200 mg injected intravenously in
C57BL6/J or C1q/ mice. Kidneys were harvested after perfusion
with normal saline to remove intravascular blood before analysis
on an infrared imaging system (Odyssey e Licor). Integrated den-
sity values (IDV) were obtained for each kidney as the sum of pixel
intensities after background corrections.
3. Results
3.1. R4A antibody binds to human complement C1q
The anti-dsDNA antibody R4A bound to the EADYG peptide and
to C1q in a dose-dependent manner (Fig. 1a and b). In addition,
peptides EADYG and DWEYS both inhibited R4A binding to C1q
(Fig. 1c) while C1q inhibited R4A binding to dsDNA (Fig. 1d). These
results demonstrate that R4A binds dsDNA, C1q and the two pep-
tides. In an attempt to identify the region of C1q that is bound by
R4A, we performed binding experiments with puriﬁed collagen tail
of C1q. R4A did not bind C1q collagen tail suggesting that the
binding site is present in the globular region of C1q (Fig. 1e), which
possesses the GSEADSV sequence.
We next tested whether R4A bound isolated glomeruli from
wild type and C1q/C57BL6/J mice. R4A antibody strongly stained
glomeruli from wild type mice both before and after DNAse treat-
ment (Fig. 1f). In contrast, R4A bound glomeruli from C1q/ mice
Fig. 2. Reactivity of human anti-DWEYS and anti-C1q antibodies. a. Human afﬁnity puriﬁed anti-DWEYS antibodies and control IgG were assayed by ELISA for binding to C1q,
EADYG peptide, dsDNA, NR2A and NR2B. b. Human monoclonal anti-DNA antibody G11 and a control monoclonal antibody B1 were assayed by ELISA for binding to C1q, EADYG
peptide and DNA. c. G11 and B1 antibody were assayed for binding to glomeruli from wild type or C1q/ mice in the presence or absence of C1q or DNAse. DAPI was used to
visualize DNA. d. Anti-C1q and B1 antibody were assayed for binding to glomeruli from wild type mice in the presence or absence of C1q or DNAse.
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mice injected intravenously with R4A had lower levels of antibody
deposition in their kidney than wild type mice (Fig. 1g). AF488-
labeled R4A was shown to deposit in glomeruli after intravenous
injection of C57BL6/J mice (Fig. 1h).
3.2. Anti-DWEYS antibody puriﬁed from serum of lupus patients
binds to C1q
Afﬁnity puriﬁed DWEYS-reactive antibodies from serum of
three lupus patients were shown to bind C1q, EADYG peptide,
dsDNA, NR2A and NR2B (Fig. 2a).
3.3. A monoclonal antibody obtained from lupus patients bind DNA,
C1q and EADYG peptide and bind glomeruli ex vivo
G11, a human monoclonal antibody obtained by cloning of Ig
genes from a peripheral blood B cell of a lupus patient and previ-
ously shown to bind to dsDNA and DWEYS peptide, was demon-
strated to bind both C1q and EADYG as well (Fig. 2b). Moreover, like
R4A, G11 bound glomeruli from wild type mice before and after
DNAse treatment but bound glomeruli from C1q/ mice prior to,
but considerably less, after DNAse treatment (Fig. 2c). B1, a human
monoclonal antibody with no reactivity to DNA or DWEYS failed to
bind glomeruli from either mouse strain. A commercial anti-C1q
monoclonal antibody was shown to bind glomeruli (Fig. 2d); this
binding was not affected by DNAse treatment. Soluble C1q partially
decreased the binding of G11 or anti-C1q to glomeruli from C57BL6/
J mice but failed to decrease binding of these antibodies to
glomeruli of C1q/ mice.
4. Discussion
In this study we demonstrate for the ﬁrst time that a subset of
anti-DNA antibodies cross-reactswith C1q aswell as the N-methyl-D-
aspartate receptor (NMDAR). The presence of anti-C1q antibodies in
lupus is well established, however the possibility of anti-DNA anti-
bodies cross-reactivewith C1q had not been proposed until now. Our
laboratory has previously shown that the R4A monoclonal antibody
which binds both DNA and the DWEYS pentapeptide was found to
bind the WCEADYGRCP decapeptide. Moreover, this sequence con-
tains the sequence EADYG that is homologous to a sequence that is
present in C1q. Therefore we carried out binding experiments
showing that R4A bound both EADYG and C1q. Since EADYG differs
from the consensus pentapeptide D/EWD/EYS/G by 1 amino acid, we
next demonstrated that R4A binding to C1q could be inhibited by
both the DWEYS and EADYG peptides. It is also important to note that
R4A binding to C1q is not limited to solid phase butwewere also able
to show that R4A binds ﬂuid phase C1q through inhibition of binding
to immobilized dsDNA. The proposed binding site of R4A in C1q is in
the globular region since it did not bind isolated collagen tail. This
would be in agreement with the observation that the majority of
anti-C1q antibodies found in lupus patients are against the globular
region of C1q [30e33].
Lupus nephritis can be initiated by the deposition of anti-dsDNA
antibody in glomeruli. R4A has been shown to bind glomeruli even
after removal of exposed DNA binding sites through DNAse treatment.
We considered, therefore, that R4A might bind C1q present in
glomeruli. The study of antibody binding to isolated glomeruli has been
used as a surrogate model for anti-DNA antibody binding in vivo and
may identify nephritogenic potential of these antibodies. Our results
demonstrate that C1q is a major target antigen in wild type glomeruli.
These results were in agreement with data from in vivo experiments of
R4A binding to kidney of wild type but not C1q/ mice.In an attempt to investigate whether similar cross-reactive an-
tibodies could be found in patients with lupus, we demonstrated
that anti-DWEYS antibodies from lupus patients also showed cross-
reactivity to DNA, C1q, EADYG peptide, NR2A and NR2B. In addition,
a humanmonoclonal antibody to DNA (G11) was also found to bind
to isolated glomeruli and C1q was a major target antigen as well,
similar to what we observed for R4A. Soluble C1q was able to
partially inhibit binding of G11 and anti-C1q to glomeruli from
C57BL6/J mice; however, this inhibition was not observed in
glomeruli from C1q/mice.We interpret this result to suggest that
C1q binds DNA in glomeruli of wild type mice; soluble C1q inhibits
the binding of R4A to either DNA or C1q. In contrast, when soluble
C1q is added to C1q/ glomeruli, it binds to DNA and is a target
antigen for G11, thereby enhancing binding of G11.
The normal plasma concentrations of C1q range between 100
and 200 mg/ml; thus, the concentration of C1q in plasma is sufﬁ-
cient for in vivo antibody binding. This cross-reactivity appears
crucial in the binding of this subset of anti-DNA antibodies to
glomeruli. This observation helps explain the multiple studies
showing that anti-C1q antibodies are present in approximately 50%
of lupus patients, almost exclusively in patients who also harbor
anti-dsDNA antibodies, and are highly predictive of renal disease.
There are a number of studies that show the critical contribution
of DCs to glomerulonephritis [34]. Anti-C1q antibodies could
contribute to IC-mediated glomerulonephritis by enhancing IC
deposition in glomeruli. We postulate R4A-like antibodies may also
bind and remove soluble C1q, thus cause a functional deﬁciency of
C1q and enhanced systemic inﬂammation and DC activation [35].
Overall, these studies demonstrate a novel cross-reactivity be-
tween DNA and C1q and provide evidence supporting a role for
cross-reactive antibodies in SLE.
5. Conclusions
Our data demonstrate that a subset of anti-dsDNA antibodies
cross-react with C1q and deposit in the kidney. We propose that
anti-C1q antibodies could contribute to the development of IC-
mediated glomerulonephritis by direct binding to glomeruli or by
removal of soluble C1q.
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